These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
279 related items for PubMed ID: 15464320
1. Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. Inoue T, Uchida T, Sakuma M, Imoto Y, Ozeki Y, Ozaki Y, Hikichi Y, Node K. J Am Coll Cardiol; 2004 Oct 06; 44(7):1408-14. PubMed ID: 15464320 [Abstract] [Full Text] [Related]
2. Stent-induced expression and activation of the leukocyte integrin Mac-1 is associated with neointimal thickening and restenosis. Inoue T, Uchida T, Yaguchi I, Sakai Y, Takayanagi K, Morooka S. Circulation; 2003 Apr 08; 107(13):1757-63. PubMed ID: 12665491 [Abstract] [Full Text] [Related]
3. Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation. Lee BK, Lee SW, Park SW, Lee SW, Park DW, Kim YH, Lee CW, Hong MK, Kim JJ, Jang S, Chi HS, Park SJ. Am J Cardiol; 2007 Aug 15; 100(4):610-4. PubMed ID: 17697815 [Abstract] [Full Text] [Related]
4. Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation. Kozuma K, Hara K, Yamasaki M, Morino Y, Ayabe S, Kuroda Y, Tanabe K, Ikari Y, Tamura T. Am Heart J; 2001 Jan 15; 141(1):124-30. PubMed ID: 11136497 [Abstract] [Full Text] [Related]
5. Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis. Kamishirado H, Inoue T, Mizoguchi K, Uchida T, Nakata T, Sakuma M, Takayanagi K, Morooka S. Am Heart J; 2002 Aug 15; 144(2):303-8. PubMed ID: 12177649 [Abstract] [Full Text] [Related]
6. Comparison of dual versus triple antiplatelet therapy after drug-eluting stent according to stent length (from the pooled analysis of DECLARE trials). Lee SW, Lee JY, Ahn JM, Park DW, Han S, Park YK, Lee WS, Jang JY, Kwon CH, Park GM, Cho YR, Kim WJ, Kang SJ, Kim YH, Lee CW, Kim JJ, Park SW, Park SJ. Am J Cardiol; 2013 Dec 01; 112(11):1738-44. PubMed ID: 24063835 [Abstract] [Full Text] [Related]
7. A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent. Chen YD, Lu YL, Jin ZN, Yuan F, Lü SZ. Chin Med J (Engl); 2006 Mar 05; 119(5):360-6. PubMed ID: 16542577 [Abstract] [Full Text] [Related]
8. Pre-procedural expression of Mac-1 and LFA-1 on leukocytes for prediction of late restenosis and their possible correlation with advanced coronary artery disease. Rahimi K, Maerz HK, Zotz RJ, Tárnok A. Cytometry B Clin Cytom; 2003 May 05; 53(1):63-9. PubMed ID: 12717693 [Abstract] [Full Text] [Related]
9. RACTS: a prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: long-term clinical and angiographic outcome. Ge J, Han Y, Jiang H, Sun B, Chen J, Zhang S, Du Z, RACTS (Randomized Prospective Antiplatelet Trial of Cilostazol Versus Ticlopidine in Patients Undergoing Coronary Stenting) Trial Investigators. J Cardiovasc Pharmacol; 2005 Aug 05; 46(2):162-6. PubMed ID: 16044027 [Abstract] [Full Text] [Related]
10. Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine. Tanabe Y, Ito E, Nakagawa I, Suzuki K. Int J Cardiol; 2001 May 05; 78(3):285-91. PubMed ID: 11376832 [Abstract] [Full Text] [Related]
11. Comparison of cilostazol and clopidogrel after successful coronary stenting. Lee SW, Park SW, Hong MK, Lee CW, Kim YH, Park JH, Kang SJ, Han KH, Kim JJ, Park SJ. Am J Cardiol; 2005 Apr 01; 95(7):859-62. PubMed ID: 15781016 [Abstract] [Full Text] [Related]